This study found a higher proportion of HER2 positive tumors among patients with the A/A germline genotype, compared to homozygous G/G breast cancer patients (26.3% vs 15.2%, respectively, p=0.008) (1). This evidence concerns the gene ERBB2 and breast carcinoma.